The funds will allow the company to continue a Phase I/II trial of its CDK2 inhibitor in certain hard-to-treat biomarker-defined cancers.

NEW YORK – GSK will roll out its anti-PD-1 therapy Jemperli (dostarlimab) for certain endometrial cancer patients and its PARP inhibitor Zejula (niraparib) for ovarian cancer patients in India.

Collaborators from various institutions will leverage the latest multi-disciplinary drug development tools to produce tailored treatment and prevention strategies.

A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.

Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.